NewEdge Wealth LLC Purchases Shares of 11,326 Zimmer Biomet Holdings, Inc. $ZBH

NewEdge Wealth LLC purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,326 shares of the medical equipment provider’s stock, valued at approximately $975,000.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at $204,000. Sivia Capital Partners LLC bought a new position in Zimmer Biomet during the 2nd quarter worth $232,000. United Bank lifted its holdings in Zimmer Biomet by 10.7% during the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after buying an additional 1,153 shares during the period. Federated Hermes Inc. grew its position in shares of Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 1,202 shares during the last quarter. Finally, Cerity Partners LLC grew its position in shares of Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after buying an additional 37,116 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH stock opened at $101.01 on Friday. The firm has a market cap of $19.27 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 2.69 and a beta of 0.45. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The stock has a 50-day moving average price of $92.64 and a 200-day moving average price of $91.00. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $2.01 by $0.06. The company had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ZBH shares. Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, August 4th. UBS Group reiterated a “buy” rating and issued a $120.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Wells Fargo & Company lowered their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, April 29th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Finally, Citigroup reduced their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $104.42.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.